HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...
While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to deliver life-changing brain health medicines. The company is committed to ...
Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...
10d
Hosted on MSNSAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock UpSage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...
Robert Kennedy Jr. indicated he would consider authorizing the government to seize patents of high-priced medicines to lower ...
10d
GlobalData on MSNSage rejects Biogen’s $469m takeover bidSage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...
Anti-abortion groups aren’t lobbying against RFK Jr., U.S. reported first case of H5N9 bird flu strain, Sage Therapeutics ...
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results